Primary peritoneal cancer Trials in Toronto, Canada
Conditions / Primary peritoneal cancer / Toronto, Canada
Clinical trials for Primary peritoneal cancer investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | TERMINATED | PHASE3 |
| NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | RECRUITING | — |
| NCT05065021 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | UNKNOWN | PHASE2 |
| NCT01204749 | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | COMPLETED | PHASE3 |
| NCT00489359 | Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | TERMINATED | PHASE2/PHASE3 |
| NCT01883297 | Re-Stimulated TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | COMPLETED | PHASE2 |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study | RECRUITING | PHASE1/PHASE2 |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | TERMINATED | PHASE3 |